TY  - JOUR
PY  - 2016//
TI  - A double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment-resistant depression
JO  - Psychiatry and the Clinical Neurosciences
A1  - Mehdi, Syed A.
A1  - Atlas, Steven E.
A1  - Qadir, Sidra
A1  - Musselman, Dominique
A1  - Goldberg, Sharon
A1  - Woolger, Judi M.
A1  - Corredor, Raul
A1  - Abbas, Muhammad Hasnain
A1  - Arosemena, Leopoldo
A1  - Caccamo, Simone
A1  - Campbell, Carmen
A1  - Farooqi, Ashar
A1  - Gao, Jinrun
A1  - Konefal, Janet
A1  - Lages, Lucas C.
A1  - Lantigua, Laura
A1  - Lopez, Johanna
A1  - Padilla, Vanessa
A1  - Rasul, Ammar
A1  - Ray, Anna M.
A1  - Simões, Herbert
A1  - Tiozzo, Eduard
A1  - Lewis, John E.
SP  - 204
EP  - 211
VL  - 71
IS  - 3
N2  - AIM: Treatment-resistant depression patients are more likely to suffer from comorbid physical and mental disorders, experience marked and protracted functional impairment, and incur higher healthcare costs than non-affected individuals. Magnesium sulfate is a treatment option that may offer great potential for patients with treatment-resistant depression based on prior work in animals and humans. <br><br>METHODS: Twelve subjects with mild or moderate treatment-resistant depression were randomized into a double-blind crossover trial to receive an infusion of 4 gram of magnesium sulfate in 5% dextrose or placebo infusion of 5% dextrose with a 5-day washout in between the 8-day intervention period. Subjects were assessed before and after the intervention for serum and urine magnesium, lipid panel, the Hamilton Rating Scale for Depression, and the Patient Health Questionnaire-9. <br><br>RESULTS: We found a difference in serum magnesium from day 2 to day 8 (pre-infusion) (p < 0.002) and from baseline to day 8 (p < 0.02). No changes were noted on the Hamilton Rating Scale for Depression or the Patient Health Questionnaire-9 24-hours post-treatment, but as serum magnesium increased from baseline to day 7, the Patient Health Questionnaire-9 decreased from baseline to day 7 (p = 0.02). <br><br>CONCLUSION: Magnesium sulfate did not significantly affect depression 24 hours post-infusion, but other results were consistent with the literature. The association between changes in serum magnesium and Patient Health Questionnaire-9 supports the idea that magnesium sulfate may be used to address treatment-resistant depression, an ongoing medical challenge. CLINICALTRIALS.GOV IDENTIFIER: https://clinicaltrials.gov/ct2/show/ NCT01597167.<br><br>This article is protected by copyright. All rights reserved.<p />  <p>Language: en</p>
LA  - en
SN  - 1323-1316
UR  - http://dx.doi.org/10.1111/pcn.12480
ID  - ref1
ER  -